BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Press Releases

  Verdiva Bio Presents Preclinical Data on VRB-103, a Selective Oral Amylin Peptide Analog, at 62nd EASD Annual Meeting

  September 29, 2026

   · 

  3 min read
• Press Releases

  uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

  September 29, 2026

   · 

  14 min read
• Press Releases

  Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - September 29, 2026

  September 29, 2026

   · 

  5 min read
• Press Releases

  Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million

  September 29, 2026

   · 

  5 min read
• Press Releases

  Ocugen to Participate in Upcoming October 2026 Investor and Industry Conferences

  September 29, 2026

   · 

  2 min read
• Press Releases

  PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026

  September 29, 2026

   · 

  4 min read
• Press Releases

  Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

  September 29, 2026

   · 

  15 min read
• Press Releases

  BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

  September 29, 2026

   · 

  10 min read
• Press Releases

  OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

  September 29, 2026

   · 

  1 min read
• Press Releases

  Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis

  September 29, 2026

   · 

  7 min read